Bank Hapoalim BM’s Scinai Immunotherapeutics SCNI Stock Holding History

Bank Hapoalim BM’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-65	Closed	-$254	–	203
2020 Q3	$254	Sell	65 -26	-29%	-$99.8K	0.01%	157
2020 Q2	$207K	Buy	+91	New	+$147K	0.05%	174
2020 Q1	–	Sell	-249	Closed	-$232K	–	184
2019 Q4	$232K	Hold	249	–	–	0.05%	157
2019 Q3	$148K	Hold	249	–	–	0.04%	162
2019 Q2	$144K	Hold	249	–	–	0.04%	169
2019 Q1	$135K	Hold	249	–	–	0.03%	161
2018 Q4	$119K	Sell	249 -3	-1%	-$1.62K	0.04%	150
2018 Q3	$141K	Sell	252 -17	-6%	-$10.1K	0.03%	177
2018 Q2	$180K	Hold	269	–	–	0.05%	177
2018 Q1	$146K	Buy	+269	New	+$168K	0.04%	179

Other funds holding SCNI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Bank Hapoalim BM's SCNI Position: Q4 2020 in Review

Bank Hapoalim BM sold out of Scinai Immunotherapeutics (SCNI) in Q4 2020, closing a stake of 65 shares — an estimated $254 sold.

Bank Hapoalim BM first reported a position in SCNI in Q1 2018 and held it in 10 quarters. The position peaked at $232K in Q4 2019. 13 funds tracked by Wall St. Rank hold SCNI as of Q4 2020.

Bank Hapoalim BM reported no remaining Scinai Immunotherapeutics position as of Q4 2020 after selling out during the quarter.
Bank Hapoalim BM sold 65 Scinai Immunotherapeutics shares in Q4 2020, an estimated $254.
Bank Hapoalim BM first reported a position in Scinai Immunotherapeutics in Q1 2018 and held it in 10 quarters.
Bank Hapoalim BM's Scinai Immunotherapeutics position peaked at $232K in Q4 2019.
13 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2020.

Based on Bank Hapoalim BM's 13F filing for Q4 2020, filed 3 Feb 2021.